Skip to main content

Table 1 Basal characteristics of patients with PH divided by PH sub-group

From: Vitamin D deficiency among patients with pulmonary hypertension

PH subgroupsTotal (n = 53)Idiopathic (n = 16)CTD (n = 9)Congenital (n = 16)HIV (n = 6)Toxic (n = 1)CTEPH (n = 5)p value
Age (years;  x ± SD)40.8 ± 16.538.5 ± 19.153 ± 14.933.2 ± 15.542.7 ± 6.44745.4 ± 11.70.10
Females (%)73.681.251007566.60400.04
FC (%)I–II71.262.544.410033.31001000.01
III–IV28.837.566.6066.7000.01
Ht (%;  x ± SD)43.9 ± 8.942.8 ± 5.740.3 ± 5.350.7 ± 11.4 *38.8 ± 9.142.142.1 ± 7.90.03
Urea (mg/ml;  x ± SD)34.49 ± 12.132.63 ± 9.632.50 ± 12.136.92 ± 17.133.33 ± 11.63438 ± 5.20.91
Creatinine (mg/dl;  x ± SD)0.96 ± 0.90.76 ± 0.10.9 ± 0.11.29 ± 1.70.71 ± 0.11.40.98 ± 0.10.69
Sodium (mEq/Lt;  x ± SD)140.4 ± 2.6139.7 ± 2.2142.7 ± 2.2140.4 ± 2.3140.2 ± 2.8141138.8 ± 3.20.13
Bilirubine (mg/dl;  x ± SD)1.14 ± 11.14 ± 0.90.72 ± 0.11 ± 0.31.21 ± 1.312.08 ± 2.20.35
6-min walk test ( x ± SD)
 Distance (m)392.5 ± 132.2395.8 ± 114337.2 ± 136.7440.5 ± 114.5294.1 ± 160.7557430 ± 146.20.11
 Saturated O2, basal (%)94.5 ± 5.396.7 ± 3.395.1 ± 1.290.8 ± 7.9 *96.3 ± 1.39895.25 ± 2.80.04
 Desaturation−6.20 ± 6−5.33 ± 5.52−8.33 ± 3.93−9.07 ± 7.2−2.67 ± 4.76−1−2.75 ± 4.990.14
 Borg basal0.42 ± 0.860.57 ± 1.010.86 ± 1.180.17 ± 0.570.42 ± 0.80000.50
 Borg final3.35 ± 2.363.57 ± 2.343.93 ± 3.142.50 ± 2.064 ± 2.3633 ± 2.580.79
Haemodynamic variables ( x ± SD)
 SBP (mmHg)116.18 ± 17.76110 ± 16.16126.44 ± 18.37114.45 ± 19.6113.33 ± 17.51135117.5 ± 12.580.31
 DBP (mmHg)71.25 ± 10.5971.23 ± 10.1073.22 ± 15.0367.73 ± 8.1770 ± 8.948575 ± 100.60
 HR (bts/min)81.9 ± 1380.8 ± 15.183.4 ± 14.380 ± 11.488.2 ± 12.67980.3 ± 13.50.89
 MPAP (mmHg)50.6 ± 17.755.7 ± 16.645.3 ± 656.7 ± 28.651.4 ± 7.72938.8 ± 10.80.24
 PAWP (mmHg)10.9 ± 3.211 ± 2.79.8 ± 3.411.8 ± 4.712.2 ± 2.3810 ± 2.50.63
 RAP (mmHg)8.6 ± 4.28.6 ± 4.58.1 ± 3.59.3 ± 3.210 ± 5.128.4 ± 5.70.66
 PVR (Wood units)8.71 ± 4.049.27 ± 2.348.88 ± 3.078.43 ± 7.0510.44 ± 4.403.96.57 ± 3.480.56
 CI (bts/min/m2)2.73 ± 0.912.7 ± 0.692.12 ± 0.343.38 ± 1.332.4 ± 0.333.82.9 ± 1.130.07
Treatment
 Oral anticoagulation (n)24863214
 Calcium channel blockers (n)11432101
 PDE5 inhibitors (n)3411610403
 Endothelin antagonists (n)11415100
 Prostanoids (n)3300000
  1. *p  < 0.05 vs rest of sub-groups. BTS beats; CI cardiac Index; CTD connective tissue disorder; CTEPH chronic thromboembolic pulmonary hypertension; DBP diastolic blood pressure; FC functional class; Ht hematocrit; HR heart rate; MPAP mean pulmonary artery pressure; PAWP pulmonary artery wedge pressure; PDE phosphodiesterase; PVR pulmonary vascular resistance; RAP right atrial pressure; SBP systolic blood pressure; Vit D vitamin D